Cartesian Therapeutics (RNAC) Payables (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Payables for 12 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables fell 23.8% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 23.8% YoY), while the FY2025 annual figure was $1.3 million, up 347.22% from the prior year.
• Payables rose to $1.6 million in Q1 2026 per RNAC's latest filing, from $1.3 million in the prior quarter.
• Across five years, Payables topped out at $31.5 million in Q4 2023 and bottomed at $214000.0 in Q3 2022.
• Historically, Payables has averaged $2.9 million across 5 years, with a median of $693000.0 in 2022.
• Annual changes were most pronounced in 2023 — Payables jumped 9854.75% — and 2024, when it tumbled 99.08%.
• Cartesian Therapeutics' Payables stood at $316000.0 in 2022, then surged by 9854.75% to $31.5 million in 2023, then sank by 99.08% to $288000.0 in 2024, then jumped by 347.22% to $1.3 million in 2025, then advanced by 24.07% to $1.6 million in 2026.
• Business Quant data shows RNAC's Payables at $1.6 million in Q1 2026, $1.3 million in Q4 2025, and $2.2 million in Q3 2025.